Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.
Schimpf
K
K
Schwarz
P
P
Kunschak
M
M
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D005164:Factor IX / Q000276:immunology* / Q000302:isolation & purification / Q000627:therapeutic use; D005169:Factor VIII / Q000276:immunology* / Q000302:isolation & purification / Q000627:therapeutic use; D006467:Hemophilia A / Q000276:immunology* / Q000628:therapy; D002836:Hemophilia B / Q000276:immunology* / Q000628:therapy; D006801:Humans; D007223:Infant; D007518:Isoantibodies / Q000096:biosynthesis / Q000097:blood*; D011446:Prospective Studies; D012449:Safety
D007518:Isoantibodies; D005169:Factor VIII; D005164:Factor IX